Summary by Futu AI
Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. conducted multiple share repurchases of A shares from March 11 to April 17, 2024. According to the Company's Next Day Disclosure Report, the Company repurchased a total of millions of shares of Class A during the above period, with detailed records of the number of shares repurchased and the date of the change. The repurchase price presents a different degree of discount or premium compared to the market price. The move is in accordance with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited and the Company has confirmed that all transactions are conducted in accordance with local rules. THIS SHARE REPURCHASE BY YAKMING KAND MAY HAVE AN IMPACT ON THE COMPANY'S SHARE PRICE AND SHAREHOLDERS' EQUITY.